These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31100312)

  • 1. Unprecedently high targeting specificity toward lung ICAM-1 using 3DNA nanocarriers.
    Roki N; Tsinas Z; Solomon M; Bowers J; Getts RC; Muro S
    J Control Release; 2019 Jul; 305():41-49. PubMed ID: 31100312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuning Design Parameters of ICAM-1-Targeted 3DNA Nanocarriers to Optimize Pulmonary Targeting Depending on Drug Type.
    Roki N; Solomon M; Bowers J; Getts L; Getts RC; Muro S
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
    Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
    J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.
    Muro S; Dziubla T; Qiu W; Leferovich J; Cui X; Berk E; Muzykantov VR
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1161-9. PubMed ID: 16505161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.
    Papademetriou IT; Garnacho C; Schuchman EH; Muro S
    Biomaterials; 2013 Apr; 34(13):3459-66. PubMed ID: 23398883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.
    Hsu J; Bhowmick T; Burks SR; Kao JP; Muro S
    J Biomed Nanotechnol; 2014 Feb; 10(2):345-54. PubMed ID: 24738342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.
    Calderon AJ; Bhowmick T; Leferovich J; Burman B; Pichette B; Muzykantov V; Eckmann DM; Muro S
    J Control Release; 2011 Feb; 150(1):37-44. PubMed ID: 21047540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.
    Papademetriou I; Tsinas Z; Hsu J; Muro S
    J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra- and trans-cellular delivery of enzymes by direct conjugation with non-multivalent anti-ICAM molecules.
    Ghaffarian R; Roki N; Abouzeid A; Vreeland W; Muro S
    J Control Release; 2016 Sep; 238():221-230. PubMed ID: 27473764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice.
    Mane V; Muro S
    Int J Nanomedicine; 2012; 7():4223-37. PubMed ID: 22915850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance.
    Kim J; Sinha S; Solomon M; Perez-Herrero E; Hsu J; Tsinas Z; Muro S
    Biomaterials; 2017 Dec; 147():14-25. PubMed ID: 28923682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.
    Garnacho C; Dhami R; Solomon M; Schuchman EH; Muro S
    Mol Ther; 2017 Jul; 25(7):1686-1696. PubMed ID: 28606376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.
    Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S
    J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy.
    Li SJ; Wang XJ; Hu JB; Kang XQ; Chen L; Xu XL; Ying XY; Jiang SP; Du YZ
    Drug Deliv; 2017 Nov; 24(1):402-413. PubMed ID: 28165814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium.
    Rossin R; Muro S; Welch MJ; Muzykantov VR; Schuster DP
    J Nucl Med; 2008 Jan; 49(1):103-11. PubMed ID: 18077519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
    Garnacho C; Muro S
    J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice.
    Garnacho C; Serrano D; Muro S
    J Pharmacol Exp Ther; 2012 Mar; 340(3):638-47. PubMed ID: 22160267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.
    Hsu J; Rappaport J; Muro S
    Pharm Res; 2014 Jul; 31(7):1855-66. PubMed ID: 24558007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.
    Bhowmick T; Berk E; Cui X; Muzykantov VR; Muro S
    J Control Release; 2012 Feb; 157(3):485-92. PubMed ID: 21951807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.
    Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA
    Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.